Four New Sterile Injection Production Facilities of Ethica Industri Farmasi Ready to Operate and Expand Market Reach

CIKARANG, March 3, 2026 – PT Ethica Industri Farmasi (“PT EIF”), a pharmaceutical company specializing in sterile injectable products and part of PYFA, has completed the construction of its production capacity expansion, Line 3, which is scheduled to be officially inaugurated in April 2026. Currently, the capacity of Line 3 has already reached full capacity, prompting the Company to accelerate the development of Line 4, Line 5, and Line 6 production facilities.

Construction of Line 3 began in September 2024 and was completed within approximately 1.5 years. This accelerated development reflects the Company’s response to increasing market demand, particularly from hospitals. In addition, the presence of Line 3 is expected to boost production productivity by up to threefold, while strengthening the Company’s capacity to produce sterile pharmaceutical preparations.

In line with this capacity increase, PT EIF is also currently developing Line 4 and Line 5. Line 4 will adopt the latest technologies in sterile pharmaceutical manufacturing. Similar technologies will also be implemented in Line 5 to ensure that product quality and safety remain well maintained. These expanded facilities are designed with advanced and modern production technologies that comply with current Good Manufacturing Practices (cGMP) standards in Indonesia and internationally, including PIC/S requirements, as well as European Union Good Manufacturing Practices (EU GMP) and the Therapeutic Goods Administration (TGA) of Australia. This demonstrates Ethica Industri Farmasi’s readiness to penetrate broader global markets.

The introduction of Line 4 and Line 5 is expected to improve production efficiency while ensuring that stringent quality standards are consistently met. At the same time, the development of production facilities will not stop at Line 5. Following the completion of Line 4 and Line 5, Ethica Industri Farmasi will also proceed with the construction of Line 6 as part of its ongoing manufacturing capacity expansion.

This strategic move comes as a direct response to the growing demand for sterile pharmaceuticals in both global and regional markets. According to various industry reports, the global sterile injectable market is projected to continue expanding significantly, with its value estimated to reach approximately USD 4.9 billion by 2026 and potentially grow to nearly USD 9.9 billion by 2035, driven by an annual growth rate of around 8%. The Asia-Pacific region is expected to be one of the largest contributors to this growth, supported by rising healthcare expenditure, expansion of medical facilities, and increasing demand for injectable and sterile pharmaceutical products. These conditions underscore the importance of reliable, high-quality, and internationally standardized sterile drug manufacturing facilities to maintain supply chain sustainability at the regional level.

Bejo Stefanus, Director of PYFA, emphasized that the development of these production facilities forms an integral part of the Company’s long-term strategy.

“The completion of Line 3, which will soon be inaugurated, marks an important milestone in enhancing our production productivity. The implementation of advanced technologies in Line 4 and Line 5 is intended to further improve product quality and safety. Looking ahead, the development of Line 6 will be part of the Company’s commitment to strengthening its manufacturing capacity,” he stated.

The addition and development of these production lines are expected to significantly strengthen the capabilities of Ethica Industri Farmasi and enhance PYFA’s competitiveness. This initiative reaffirms the Company’s commitment to continuing its role as a key player in the sterile pharmaceutical industry.